title: [Hypersensitivity reactions to carboplatin and paclitaxel - our five-years experiences].
abstract: OBJECTIVE
  To analyze hypersensitivity reactions to carboplatin and paclitaxel in patients treated with systemic administration of chemotherapy (carboplatin and/or paclitaxel).
  
  
  METHODS
  Retrospective study.
  
  
  METHODS
  Department of Obstetrics and Gynecology, Charles University in Prague, Faculty of Medicine and University Hospital Hradec Kralove.
  
  
  METHODS
  One hundred-forty patients treated with systemic administration of chemotherapy were enrolled to our study between years 2008 and 2012. The presence and the grade [grade (G) 1-5; 1 = moderate, 5 = death] of hypersensitivity reactions (HSRs) were evaluated, as well as the influence of some clinical parameters on development of HSR.
  
  
  RESULTS
  In total 29 HSRs in 21 patients were analyzed. To carboplatin were reported 19 (66%) HSRs: 13 (45%) HSRs of G1-G3 and 6 (21%) HSRs of G4. To paclitaxel were reported 10 (34%) HSRs: 9 (31%) HSRs of G1-G3 and 1 (3%) HSR of G4. The number of administered cycles of carboplatin to develop G1-G4 resp. G1-G3 HSR was higher in comparison with number of cycles to develop HSR of the same grade to paclitaxel(p = 0.001, resp. p = 0.01).
  
  
  CONCLUSIONS
  HSR to carboplatin is unlike paclitaxel affected by the number of administered cycles. This fact should be included in the clinical management of patients treated with intravenous chemotherapy using carboplatin.
authors.forename: A
authors.initials: A
authors.lastname: Rezáč
authors.forename: P
authors.initials: P
authors.lastname: Jílek
authors.forename: V
authors.initials: V
authors.lastname: Rezáčová
authors.forename: P
authors.initials: P
authors.lastname: Skapinec
authors.forename: I
authors.initials: I
authors.lastname: Sedláková
authors.forename: J
authors.initials: J
authors.lastname: Tošner
authors.forename: J
authors.initials: J
authors.lastname: Spaček
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000494:pharmacology; D016190:Carboplatin / Q000494:pharmacology*; D018153:Czech Republic / Q000453:epidemiology; D004342:Drug Hypersensitivity / Q000453:epidemiology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D008297:Male; D017239:Paclitaxel / Q000494:pharmacology*; D012189:Retrospective Studies; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D016190:Carboplatin; D017239:Paclitaxel